At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCWB HCW Biologics Inc.
Closed 08-28 16:00:00 EDT
3.43
+0.26
+8.20%
盘后3.31
-0.12-3.50%
19:38 EDT
High3.43Low3.00Vol127.55K
Open3.20D1 Closing3.17Amplitude13.56%
Mkt Cap6.30MTradable Cap5.66MTotal Shares1.84M
T/O413.33KT/O Rate7.73%Tradable Shares1.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HCW Biologics Says TGF-Β Trap-IL-15 Fusion Expands CD8+ T, NK Cells in Human Studies
Reuters  ·  08-25
HCW Biologics Says TGF-Β Trap-IL-15 Fusion Expands CD8+ T, NK Cells in Human Studies
HCW Biologics files to sell 1.24M shares of common stock for holders
TIPRANKS  ·  08-21
HCW Biologics files to sell 1.24M shares of common stock for holders
Cancer Immunotherapy Developer CEL-SCI's Q3 Net Loss Unchanged
Reuters  ·  08-17
Cancer Immunotherapy Developer CEL-SCI's Q3 Net Loss Unchanged
Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens
Reuters  ·  08-15
Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens
HCW Biologics Q2 EPS $(11.58), Sales $135.568K Up From $6.550K YoY
Benzinga Earnings  ·  08-15
HCW Biologics Q2 EPS $(11.58), Sales $135.568K Up From $6.550K YoY
HCW Biologics Q2 FY26 Net Loss Widens to $5.2 Million; Revenue Rises to $135,568
Reuters  ·  08-15
HCW Biologics Q2 FY26 Net Loss Widens to $5.2 Million; Revenue Rises to $135,568
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
THOMSON REUTERS  ·  08-15
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics Restates Q1 EPS, Cutting Net Income Attributable to Common Shareholders by USD 728,000
Reuters  ·  08-15
HCW Biologics Restates Q1 EPS, Cutting Net Income Attributable to Common Shareholders by USD 728,000
HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified
Benzinga Earnings  ·  08-15
HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified
HCW Biologics - Q1 2026 Financial Statements Should no Longer be Relied upon - SEC Filing
THOMSON REUTERS  ·  08-15
HCW Biologics - Q1 2026 Financial Statements Should no Longer be Relied upon - SEC Filing
HCW Biologics - Errors Constitute Material Misstatement of EPS - SEC Filing
THOMSON REUTERS  ·  08-15
HCW Biologics - Errors Constitute Material Misstatement of EPS - SEC Filing
HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing
THOMSON REUTERS  ·  08-15
HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing
HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing
THOMSON REUTERS  ·  08-15
HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing
HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement
Reuters  ·  08-15
HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement
Top Brass Makes Bold Move on HCW Biologics Shares
TIPRANKS  ·  08-01
Top Brass Makes Bold Move on HCW Biologics Shares
HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56
Reuters  ·  08-01
HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56
HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement
Reuters  ·  07-29
HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
THOMSON REUTERS  ·  07-29
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program
Reuters  ·  07-23
HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program
HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b
THOMSON REUTERS  ·  07-23
HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b

Introduction

Company Name.
HCW Biologics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Issue price:
--